



Transcriptional and epigenetic control of early life cell fate decisions

Jasmina Al-Mousawi and Ana Boskovic

Purpose of review

Global epigenetic reprogramming of the parental genomes after fertilization ensures the establishment of genome organization permissive for cell specialization and differentiation during development. In this review, we highlight selected, well-characterized relationships between epigenetic factors and transcriptional cell fate regulators during the initial stages of mouse development.

Recent findings

Blastomeres of the mouse embryo are characterized by atypical and dynamic histone modification arrangements, noncoding RNAs and DNA methylation profiles. Moreover, asymmetries in epigenomic patterning between embryonic cells arise as early as the first cleavage, with potentially instructive roles during the first lineage allocations in the mouse embryo. Although it is widely appreciated that transcription factors and developmental signaling pathways play a crucial role in cell fate specification at the onset of development, it is increasingly clear that their function is tightly connected to the underlying epigenetic status of the embryonic cells in which they act.

Summary

Findings on the interplay between genetic, epigenetic and environmental factors during reprogramming and differentiation in the embryo are crucial for understanding the molecular underpinnings of disease processes, particularly tumorigenesis, which is characterized by global epigenetic rewiring and progressive loss of cellular identity.

Keywords

cell fate, development, embryo, epigenetics, reprogramming, transcription

INTRODUCTION

Development starts at fertilization, when the sperm and egg fuse to create the zygote, which will, through subsequent cleavages and differentiation, give rise to all cells in the new organism. Following fertilization, the specialized and asymmetric epigenomic patterns of the maternal and paternal genomes are largely reset to provide a clean slate supporting the development of the new animal. Embryo-specific organization of the genome is then established with patterning gradually becoming more restricted and specialized, supporting lineage specification during embryogenesis. The first cell differentiation event during mouse development is the distinction of extraembryonic trophoblast from the pluripotent inner cell mass (ICM) during the morula/blastocyst stage, an event primarily driven by developmental signaling pathways and transcriptional master regulators of the two cell fates.

Generally considered as equipotent, the cells of the early mouse embryo preceding lineage allocation nevertheless harbor some functional differences. In

certain cases, these arise as early as two-cell stage of development, when blastomeres are considered totipotent (meaning that they can contribute to both embryonic and extraembryonic tissues). For instance, only a subset of mouse embryos contain two totipotent cells at the two-cell stage, while the majority constitute blastomere pairs in which only one of the blastomeres has the ability to singularly maintain development of a healthy blastocyst [1].

Epigenetics and Neurobiology Unit, European Molecular Biology Laboratory (EMBL), Monterotondo, Italy

Correspondence to Ana Boskovic, Epigenetics and Neurobiology Unit, European Molecular Biology Laboratory (EMBL), Via E. Ramarini 32, Monterotondo 00015 Rome, Italy. Tel: +39 690091218; e-mail: ana.boskovic@embl.it

Curr Opin Oncol 2022, 34:148–154

DOI:10.1097/CCO.0000000000000814

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

KEY POINTS

- In the early mammalian embryo, global epigenetic reprogramming followed by establishment of epigenetic patterns influences the emergence of distinct cell lineages from undifferentiated blastomeres.
- Specification of cell identity during early development is guided by the interaction of transcriptional master regulators with epigenetic factors and chromatin organization.
- Noncanonical distribution of histone and DNA modifications, and asymmetries in epigenetic factor localization are a hallmark of mouse preimplantation blastomeres, with potential to instruct lineage allocation.
- The extent to which parentally inherited epigenomic differences contribute to early embryonic prepatternning and blastomere plasticity, and influence downstream development and differentiation remains to be elucidated.

In this review, we focus on the different gene-regulatory mechanisms influencing chromatin and genome function preceding the first cell differentiation events and discuss how their dynamics and asymmetries influence lineage decisions in the mouse embryo (Fig. 1).

TRANSCRIPTION FACTORS

Transcription factors (TFs) can bind DNA cis-regulatory elements in a sequence-specific manner and modulate transcriptional output of their target genes (reviewed in [2,3]). Recruitment and binding of transcription factors to their cognate sites can be facilitated by cooperative interactions among different transcription factors and by interactions with chromatin components (reviewed in [4]).

The first lineage segregation between the pluripotent ICM and the trophectoderm, which will give rise to the placenta, is guided by lineage-specific transcription factors, resulting from a polarization of the outer cells of the morula and a subsequent activation of the Hippo signaling pathway (reviewed in [5]). Mechanistically, this pathway results in the dephosphorylation of YAP1, allowing for its nuclear translocation where it acts as a co-activator for TEAD4, forming a complex that induces expression of *Cdx2* and *Gata3*, transcriptional master regulators of the trophectoderm lineage [6,7]. The activation of the Hippo pathway leads to downregulation of the pluripotency factor *SOX2* in trophectoderm precursors, a mechanism dependent on TEAD4 but not *CDX2* [8]. *CDX2* itself is dispensable for establishment of the trophectoderm but necessary

for the maintenance of its function [9]. *CDX2* can be co-expressed with *OCT4*, a core pluripotency transcription factor, in a cross-antagonistic manner with the transcription factors inhibiting each other's activity [10,11]. Despite *Cdx2* expression, morula blastomeres retain a high level of plasticity until the 32-cell stage during which they can interconvert lineages [12]. However, shortly thereafter, cells expressing high *CDX2* levels lose their ability to convert to the ICM [13].

After blastocyst formation, the ICM further segregates into the epiblast (Epi), which will give rise to the embryo proper and differentiate into the three germ layers, and the extraembryonic primitive endoderm (PrE), which will contribute to the yolk sac (reviewed in [5]). Initially co-expressed in the early ICM [14,15], the classic Epi specifier *NANOG*, and PrE-specific transcription factor *GATA6* adopt a mutually exclusive 'salt-and-pepper' expression pattern around embryonic day (E) 3.5 [16]. Lack of either factor results in the loss of the cell lineage it specifies [17–20]. During the resolution of the ICM, there is an antagonistic relationship between *NANOG* and *GATA6* [21,23]. Nevertheless, ICM plasticity is retained beyond the bifurcation of *NANOG* and *GATA6* expression patterns, and cells can interconvert between Epi and PrE fates until E4.5 [22,23]. The PrE/Epi divergence is guided by differential Fibroblast Growth Factor (FGF) signaling and activation of the mitogen-activated protein kinase (MAPK) pathway, the action of which causes specification towards PrE [16,24,25]. Phosphorylation of MAPK-effector ERK triggers an initially reversible priming towards PrE through a redistribution of cofactors of the transcriptional machinery, leading to the suppression of pluripotency genes and allowing for the activation of PrE genes [26,27]. Expression patterns of MAPK signaling components in the early ICM are heterogeneous with Epi-precursors expressing *FGF4* ligand and PrE-precursors expressing *FGFR2* receptor [19,28,29]. Modulating the MAPK pathway in embryos shifts the PrE-to-Epi ratio, with *Fgf4*-null embryos unable to maintain *Gata6* expression [25,30,31]. In addition to *FGFR2*, *FGFR1* is expressed throughout the ICM, and its activity is involved in PrE specification, as well as allowing Epi cells to exit the earlier, naive pluripotent state and progress towards a later, primed state [32,33].

CHROMATIN MOBILITY AND LONG NON-CODING RNAs PRECEDING LINEAGE ALLOCATION

As transcription factors function within the chromatin context, it is logical to hypothesize that the




FIGURE 1. Epigenetic and transcription factors regulating cell fate allocation during mouse preimplantation development. (a) Stages of embryonic development from fertilization until implantation and (b) their respective lineage trajectories arising during early differentiation. At the morula stage, the blastomeres adopt either trophectoderm or ICM fate. The ICM subsequently differentiates into the PrE and Epi. ExEm stands for extraembryonic, Em stands for embryonic. (c) Effectors with ascribed instructive roles in the first cell fate decisions depicted below the corresponding developmental stage where they act. Initial heterogeneities are dependent on the distribution of maternally inherited factors, such as lncRNAs (zygote stage), which can impact the tethering of chromatin regulator CARM1 (two-cell stage). CARM1 is in turn associated with an increased level of pluripotency factor expression and chromatin mobility, and higher contribution of cells to the ICM (morula stage). Later, transcription factors ensure proper lineage segregation during the first (trophectoderm/ICM) and second (Epi/PrE) cell fate decisions. Around the time of implantation, DNA methylation (DNAm) and Polycomb Repressive Complexes (PRC) help guide lineage restriction. (d) Loss of DNA methylation levels during reprogramming occurs between the zygote and blastocyst stages, after which the DNA methylation levels are rapidly increased. Figure was made using Biorender.com.

interplay between genome organization and transcription factor action cumulatively contribute to cell plasticity and lineage allocation. In 2011, it was shown that the kinetics of OCT4 on chromatin in four-cell and eight-cell stage embryos differ between individual blastomeres and that differential OCT4 dynamics are predictive of lineage patterning and cell position within the embryo: cells displaying slower OCT4 kinetics are more likely to contribute to inner cells of the morula at compaction [34]. A follow-up study using photo-activatable fluorescence correlation spectroscopy in four-cell embryos found similar results for SOX2: blastomeres with

long-lived SOX2 chromatin association contribute more readily towards the pluripotent lineage, in a manner regulated by H3R26 dimethylation [35]. This histone modification, deposited by arginine methyltransferase CARM1, is found to be naturally asymmetrically distributed between cells already at the four-cell stage, depending on the cleavage plane of the two-cell stage blastomeres. Lower levels of H3R26me2 in four-cell stage blastomeres are associated with a subsequent higher propensity of these cells to contribute to trophectoderm compared with ICM [36]. Conversely, increasing H3R26me2 levels through the overexpression of CARM1 in one of the

Downloaded from http://journals.lww.com/co-oncology by BiDlMf5eP-HKav1zEoum1tQIN4a+KULhEzqshHd4XMI0hC ywCX1AMnYqP/1QIH-D3i3DD00dRy/Tv/Sf4C3V/C1y0abggQZxdg9j2MwZLel= on 01/15/2024

two-cell stage blastomeres leads to an upregulation of NANOG and SOX2 expression, as well as an increase in histone H3.1 mobility in its progeny [37], and results in higher contribution of these cells to the pluripotent ICM [36]. Presumably, higher accessibility of underlying DNA in ICM-destined cells, caused at least partly by faster histone exchange, facilitates longer and/or more stable association of pluripotency factors with embryonic chromatin.

Additionally, CARM1 has been reported to physically interact with PRDM14 and long non-coding (lnc) RNAs LincGET and Neat1, all of which have been proposed to anchor CARM1 to its cognate sites on chromatin [38,39,40]. LincGET itself is differentially expressed between the sister blastomeres already at the two-cell stage but only through interaction with CARM1 is it able to induce SOX2 and NANOG expression [40]. Similarly, it was found that depletion of Neat1 causes developmental arrest at the morula/early blastocyst stage, possibly due to increased expression of CDX2 [39]. Cumulatively, these data point to a dynamic interplay between different epigenetic players, transcription factor levels and underlying genomic context in guiding cell fate allocation during development.

CHROMATIN MODIFICATIONS IN THE EARLY EMBRYO

The first of two genome-wide waves of epigenetic reprogramming in the animal's life cycle takes place immediately after fertilization, with the presumptive aim of 'resetting' the chromatin landscape inherited from the highly specialized gametes. This establishes a clean slate of the embryonic epigenome preceding (and allowing for) cell differentiation. Below, we outline the best characterized chromatin modifications associated with regulation of embryogenesis and differentiation.

DNA methylation

DNA methylation occurs directly on the DNA molecule in a CpG dinucleotide context and is traditionally associated with transcriptional silencing (reviewed in [41]). Although overall stable in somatic tissues, DNA methylation patterns are globally reprogrammed following fertilization and during the specification of the germline.

In the early embryo, progressive loss of DNA methylation takes place, ultimately resulting in a hypomethylated genome at the blastocyst stage (Figure 1d) [42,43]. This occurs as a consequence of the absence of DNA methylation maintenance normally carried out by DNMT1 [42,43], as well as

active removal through the action of Ten-eleven Translocation (TET) enzymes. In the zygote, the paternal genome is demethylated more rapidly than the maternal one, through the action of TET3 [44–48]. Maternal chromosomes are protected from this mechanism by STELLA/Dppa3, which recognizes H3K9me2, deposited during oogenesis [49]. This distinction is not clear-cut: TET3 has been reported to demethylate parts of the maternal genome, blurring the segregation of demethylation mechanisms between the parental genomes [50–52]. Although pervasive, it is important to note that DNA demethylation in preimplantation embryos is not absolute, with imprinting control regions and some transposable elements (in particular IAPs) escaping the reprogramming process [53]. From the blastocyst stage, DNA methylation levels increase through the action of de novo DNA methyltransferases DNMT3A and DNMT3B [54]. DNA methylation is dispensable for the formation of extra-embryonic lineages [55], consistent with the reported hypomethylated states in extraembryonic tissues and the higher expression levels of DNMT3A/B in the post-implantation epiblast [56]. Despite the differential requirements and levels of DNA methylation between cell types of the blastocyst, DNA methylation asymmetries in cleavage stage blastomeres have thus far not been implicated as early regulators of the first lineage decision event as they chiefly arise following cell fate allocation.

H3K27me3 and H2AK119Ub1

Polycomb repressive complexes 1 and 2 (PRC1&2) deposit histone modifications H2A monoubiquitylation (H2AUb1) and H3K27 trimethylation (H3K27me3), respectively, which correlate with repression of gene activity and the restriction of cell fate during development in various animal model organisms [57–61]. PRC1 can be recruited to chromatin by its interaction with H3K27me3, suggesting a temporal order of PRC function on chromatin (PRC2 precedes PRC1) [62,63]. However, during preimplantation development, an asymmetric distribution exists between H3K27me3 and H2AK119Ub1 across the genome [64,65,66]. After fertilization, global erasure of H3K27me3 and targeted depletion at promoter regions occur at the paternal and maternal genomes, respectively [66–68]. A gradual gain of H3K27me3 follows between the two-cell and morula-to-blastocyst transition and in the postimplantation epiblast [71], concomitantly with the initial cell fate specifications in the embryo. Genetic studies have revealed PRC2 to be dispensable during preimplantation development but essential at the onset of

gastrulation, when cells set a course towards distinct developmental trajectories [69,70]. Interestingly, PRC2 KO has almost no effect on H2AK119Ub1 distribution in the embryo, which is expected in a somatic context [64²²,65²²,71] after a near-complete loss of H3K27me3. Conversely, in embryos, PRC1 loss-of-function phenotypes are embryonic lethal, causing developmental arrest at the two-cell stage [75]. Recently, variants of PRC1 have been implicated in mediating the noncanonical pattern of H3K27me3. PRC1 variants can mediate the recruitment of PRC2 independently of preexisting H3K27me3. PRC2 can bind H2AK119Ub1, which in turn stimulates its catalytic activity and deposition of H3K27me3 (PRC1 precedes PRC2) [64²²,65²²,72]. Thus, contrary to the dogma, preimplantation embryos are characterized by a PRC1-mediated regulation of PRC2.

H3K4me3

H3K4me3 is deposited by MLL1 and MLL2 methyltransferases (reviewed in [57]), and generally associated with promoters of actively transcribed genes. In oocytes, H3K4me3 exhibits a noncanonical pattern, which is established gradually during oogenesis through the action of MLL2 [73–75]. These noncanonical domains are broad and abundant (covering promoters, intergenic regions, distal regions and transposable elements), and found on a subset of CpG islands, regardless of their transcriptional status [73,74,76²²]. After fertilization, the pattern of H3K4me3 inherited from the oocyte is reprogrammed through the action of histone demethylases KDM5A and KDM5B [73]. Disruptions of KDM5A/B cause defects in preimplantation development and aberrant resolution of noncanonical H3K4me3 patterning in a transcription-dependent manner [74]. The paternal genome acquires broad, weak regions of H3K4me3, which are replaced by a canonical H3K4me3 pattern at the two-cell stage [74]. Interestingly, H3K4me3 is found over transposable elements at the two-cell stage, which in turn correlates with their transient developmental expression [77]. Both H3K27me3 and H3K4me3 display noncanonical patterning in the oocyte, which is rapidly erased after fertilization. What role could these unique chromatin markings play during oogenesis and are they necessary for proper progression through the earliest developmental stages? The broad distribution of these histone post-translational modifications over large genomic regions argues against their role in fine-tuned regulation of specific genes they decorate and rather points to a more general function prior to transcriptional activation of the genome.

Interestingly, a subset of developmental promoters in the embryonic epiblast harbor both H3K4me3 and the seemingly antagonistic H3K27me3 histone mark. These genomic regions are termed bivalent. Bivalency has been proposed to function as a ‘poising’ mechanism, pausing genes in an inactive or lowly expressed state, while maintaining the potential for rapid activation upon developmental cues [78–80]. The embryo contains low levels of bivalent chromatin around implantation, which increases in the Epi at peri-implantation. Whether the acquisition and/or resolution of dually marked chromatin domains can play an instructive role in the first cell fate decisions or reflects the transcriptional status of different cell types in the blastocyst remains to be elucidated.

CONCLUSION AND OUTSTANDING QUESTIONS

Despite rapid and pervasive changes in genome organization and function, cell morphology and signaling pathways, early embryogenesis is an incredibly robust and concerted process resulting in the emergence of specialized cell lineages from the same DNA content. Following the principles of regulative development [81], the fate of the cleavage-stage mouse blastomeres is not predetermined by a gradient of maternally provided factors. Nevertheless, differences in chromatin markings, transcription factor dynamics and non-coding RNA species can be detected between cells as early as the two-cell stage. Here, we discussed some of the most-understood gene-regulatory factors influencing early cell fate decisions, and while many more are being continuously uncovered and characterized (such as RNA-binding proteins and metabolites), open questions remain. How are functional asymmetries established and propagated in the near-identical cells of early embryos, and do they play a role in lineage allocation? Are distinct epigenomic patterns between blastomeres a result of differences in local concentrations of epigenetic factors found already in the zygote? How prominent is the role of stochasticity and transcriptional noise in the eventual establishment of regulatory feedback loops and downstream signal amplification? When and how do heterogeneities at the transcription factor level become sufficiently stable to induce lineage allocation, and is chromatin organization instructive during this process? Does the simultaneous expression of different lineage-specifying transcription factors prolong the developmental time window before final lineage commitment? Finally, the extent to which internal and external signals (such as environmental stress or nutrient composition) have the ability to influence the embryonic epigenome and ‘nudge’ lineage allocation at the onset

of development remains poorly understood. With our increasing ability to molecularly probe early developmental events at unprecedented spatial and temporal resolution, these exciting biological questions will undoubtedly keep developmental biology aficionados busy in the coming years.

Acknowledgements

We would like to thank Dr Carolina Galan and the members of the Boskovic lab for critically reading the manuscript and their constructive comments.

Financial support and sponsorship

The work was supported by: the European Molecular Biology Laboratory (A.B., J.A-M.). J.A-M. is supported by a PhD studentship from the Darwin Trust of Edinburgh.

Conflicts of interest

There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Casser E, Israel S, Witten A, *et al.* Totipotency segregates between the sister blastomeres of two-cell stage mouse embryos. *Sci Rep* 2017; 7:8299.
2. Vernimmen D, Bickmore WA. The hierarchy of transcriptional activation: from enhancer to promoter. *Trends Genet* 2015; 31:696–708.
3. Ong CT, Corces VG. Enhancers: emerging roles in cell fate specification. *EMBO Rep* 2012; 13:423–430.
4. Spitz F, Furlong EE. Transcription factors: from enhancer binding to developmental control. *Nat Rev Genet* 2012; 13:613–626.
5. Chazaud C, Yamanaka Y. Lineage specification in the mouse preimplantation embryo. *Development* 2016; 143:1063–1074.
6. Nishioka N, Inoue K, Adachi K, *et al.* The Hippo signaling pathway components Lats and Yap pattern *Tead4* activity to distinguish mouse trophectoderm from inner cell mass. *Dev Cell* 2009; 16:398–410.
7. Ralston A, Cox BJ, Nishioka N, *et al.* *Gata3* regulates trophoblast development downstream of *Tead4* and in parallel to *Cdx2*. *Development* 2010; 137:395–403.
8. Wicklow E, Blij S, Frum T, *et al.* HIPPO pathway members restrict *SOX2* to the inner cell mass where it promotes ICM fates in the mouse blastocyst. *PLoS Genet* 2014; 10: e1004618.
9. Strumpf D, Mao CA, Yamanaka Y, *et al.* *Cdx2* is required for correct cell fate specification and differentiation of trophectoderm in the mouse blastocyst. *Development* 2005; 132:2093–2102.
10. Niwa H, Miyazaki J, Smith AG. Quantitative expression of *Oct3/4* defines differentiation, dedifferentiation or self-renewal of ES cells. *Nat Genet* 2000; 24:372–376.
11. Niwa H, Toyooka Y, Shimosato D, *et al.* Interaction between *Oct3/4* and *Cdx2* determines trophectoderm differentiation. *Cell* 2005; 123:917–929.
12. Dietrich JE, Hiragi T. Stochastic processes during mouse blastocyst patterning. *Cells Tissues Organs* 2008; 188:46–51.
13. Posfai E, Petropoulos S, de Barros FRO, *et al.* Position- and Hippo signaling-dependent plasticity during lineage segregation in the early mouse embryo. *Elife* 2017; 6:e22906.
14. Plusa B, Piliszek A, Frankenberg S, *et al.* Distinct sequential cell behaviours direct primitive endoderm formation in the mouse blastocyst. *Development* 2008; 135:3081–3091.
15. Morgani SM, Brickman JM. LIF supports primitive endoderm expansion during preimplantation development. *Development* 2015; 142:3488–3499.
16. Chazaud C, Yamanaka Y, Pawson T, Rossant J. Early lineage segregation between epiblast and primitive endoderm in mouse blastocysts through the *Grb2*-MAPK pathway. *Dev Cell* 2006; 10:615–624.
17. Mitsui K, Tokuzawa Y, Itoh H, *et al.* The homeoprotein *Nanog* is required for maintenance of pluripotency in mouse epiblast and ES cells. *Cell* 2003; 113:631–642.
18. Frankenberg S, Gerbe F, Bessonard S, *et al.* Primitive endoderm differentiates via a three-step mechanism involving *Nanog* and RTK signaling. *Dev Cell* 2011; 21:1005–1013.
19. Bessonard S, De Mot L, Gonze D, *et al.* *Gata6*, *Nanog* and *Erk* signaling control cell fate in the inner cell mass through a tristable regulatory network. *Development* 2014; 141:3637–3648.
20. Schrode N, Saiz N, Di Talia S, Hadjantonakis AK. *GATA6* levels modulate primitive endoderm cell fate choice and timing in the mouse blastocyst. *Dev Cell* 2014; 29:454–467.
21. Singh AM, Hamazaki T, Hankowski KE, Terada N. A heterogeneous expression pattern for *Nanog* in embryonic stem cells. *Stem Cells* 2007; 25:2534–2542.
22. Grabarek JB, Zyzynska K, Saiz N, *et al.* Differential plasticity of epiblast and primitive endoderm precursors within the ICM of the early mouse embryo. *Development* 2012; 139:129–139.
23. Gardner RL, Rossant J. Investigation of the fate of 4-5 day postcoitum mouse inner cell mass cells by blastocyst injection. *J Embryol Exp Morphol* 1979; 52:141–152.
24. Nichols J, Silva J, Roode M, Smith A. Suppression of *Erk* signalling promotes ground state pluripotency in the mouse embryo. *Development* 2009; 136:3215–3222.
25. Yamanaka Y, Lanner F, Rossant J. FGF signal-dependent segregation of primitive endoderm and epiblast in the mouse blastocyst. *Development* 2010; 137:715–724.
26. Hamilton WB, Brickman JM. *Erk* signaling suppresses embryonic stem cell self-renewal to specify endoderm. *Cell Rep* 2014; 9:2056–2070.
27. Hamilton WB, Mosesson Y, Monteiro RS, *et al.* Dynamic lineage priming is driven via direct enhancer regulation by *ERK*. *Nature* 2019; 575:355–360. Here, the authors finely dissect the contribution of transcription factor binding and enhancer engagement through Mediator complex in regulation of *ERK*-signaling and cellular plasticity in embryonic stem cells.
28. Guo G, Huss M, Tong GC, *et al.* Resolution of cell fate decisions revealed by single-cell gene expression analysis from zygote to blastocyst. *Dev Cell* 2010; 18:675–685.
29. Ohnishi Y, Huber W, Tsumura A, *et al.* Cell-to-cell expression variability followed by signal reinforcement progressively segregates early mouse lineages. *Nat Cell Biol* 2014; 16:27–37.
30. Krawchuk D, Honma-Yamanaka N, Anani S, Yamanaka Y. *FGF4* is a limiting factor controlling the proportions of primitive endoderm and epiblast in the ICM of the mouse blastocyst. *Dev Biol* 2013; 384:65–71.
31. Kang M, Piliszek A, Artus J, Hadjantonakis AK. *FGF4* is required for lineage restriction and salt-and-pepper distribution of primitive endoderm factors but not their initial expression in the mouse. *Development* 2013; 140:267–279.
32. Kang M, Garg V, Hadjantonakis AK. Lineage establishment and progression within the inner cell mass of the mouse blastocyst requires *FGFR1* and *FGFR2*. *Dev Cell* 2017; 41:496.e5–510.e5.
33. Molotkov A, Mazot P, Brewer JR, *et al.* Distinct requirements for *FGFR1* and *FGFR2* in primitive endoderm development and exit from pluripotency. *Dev Cell* 2017; 41:511.e4–526.e4.
34. Plachta N, Bollenbach T, Pease S, *et al.* *Oct4* kinetics predict cell lineage patterning in the early mammalian embryo. *Nat Cell Biol* 2011; 13:117–123.
35. White MD, Angiolini JF, Alvarez YD, *et al.* Long-lived binding of *Sox2* to DNA predicts cell fate in the four-cell mouse embryo. *Cell* 2016; 165:75–87.
36. Torres-Padilla ME, Parfitt DE, Kouzarides T, Zernicka-Goetz M. Histone arginine methylation regulates pluripotency in the early mouse embryo. *Nature* 2007; 445:214–218.
37. Boskovic A, Eid A, Pontabry J, *et al.* Higher chromatin mobility supports totipotency and precedes pluripotency in vivo. *Genes Dev* 2014; 28:1042–1047.
38. Burton A, Muller J, Tu S, *et al.* Single-cell profiling of epigenetic modifiers identifies *PRDM14* as an inducer of cell fate in the mammalian embryo. *Cell Rep* 2013; 5:687–701.
39. Hupalowska A, Jedrusik A, Zhu M, *et al.* *CARM1* and paraspeckles regulate preimplantation mouse embryo development. *Cell* 2018; 175:1902.e13–1916.e13. This study shows specific nuclear recruitment of *CARM1* by main paraspeckle component and *lncRNA Neat1*. Together with Wang *et al.* 2018, this paper shows that regulation of a chromatin modifier acting in the earliest stages of development occurs through a localization mechanism by noncoding transcripts.
40. Wang J, Wang L, Feng G, *et al.* Asymmetric expression of *LincGET* biases cell fate in two-cell mouse embryos. *Cell* 2018; 175:1887–1901.e18. The authors identify long noncoding RNA *LincGET* as an interactor and upstream regulator of *CARM1*, the action of which biases blastomere fate towards the inner cell mass.
41. Greenberg MVC, Bourc'his D. The diverse roles of DNA methylation in mammalian development and disease. *Nat Rev Mol Cell Biol* 2019; 20:590–607.
42. Howell CY, Bestor TH, Ding F, *et al.* Genomic imprinting disrupted by a maternal effect mutation in the *Dnmt1* gene. *Cell* 2001; 104:829–838.
43. Inoue A, Shen L, Dai Q, *et al.* Generation and replication-dependent dilution of 5fC and 5caC during mouse preimplantation development. *Cell Res* 2011; 21:1670–1676.
44. Gu TP, Guo F, Yang H, *et al.* The role of *Tet3* DNA dioxygenase in epigenetic reprogramming by oocytes. *Nature* 2011; 477:606–610.

45. Inoue A, Zhang Y. Replication-dependent loss of 5-hydroxymethylcytosine in mouse preimplantation embryos. *Science* 2011; 334:194.
46. Iqbal K, Jin SG, Pfeifer GP, Szabo PE. Reprogramming of the paternal genome upon fertilization involves genome-wide oxidation of 5-methylcytosine. *Proc Natl Acad Sci U S A* 2011; 108:3642–3647.
47. Mayer W, Niveleau A, Walter J, *et al.* Demethylation of the zygotic paternal genome. *Nature* 2000; 403:501–502.
48. Oswald J, Engemann S, Lane N, *et al.* Active demethylation of the paternal genome in the mouse zygote. *Curr Biol* 2000; 10:475–478.
49. Nakamura T, Liu YJ, Nakashima H, *et al.* PGC7 binds histone H3K9me2 to protect against conversion of 5mC to 5hmC in early embryos. *Nature* 2012; 486:415–419.
50. Amouroux R, Nashun B, Shirane K, *et al.* De novo DNA methylation drives 5hmC accumulation in mouse zygotes. *Nat Cell Biol* 2016; 18:225–233.
51. Shen L, Inoue A, He J, *et al.* Tet3 and DNA replication mediate demethylation of both the maternal and paternal genomes in mouse zygotes. *Cell Stem Cell* 2014; 15:459–471.
52. Wang L, Zhang J, Duan J, *et al.* Programming and inheritance of parental DNA methylomes in mammals. *Cell* 2014; 157:979–991.
53. Smith ZD, Chan MM, Mikkelsen TS, *et al.* A unique regulatory phase of DNA methylation in the early mammalian embryo. *Nature* 2012; 484:339–344.
54. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. *Cell* 1999; 99:247–257.
55. Sakaue M, Ohta H, Kumaki Y, *et al.* DNA methylation is dispensable for the growth and survival of the extraembryonic lineages. *Curr Biol* 2010; 20:1452–1457.
56. Smith ZD, Shi J, Gu H, *et al.* Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer. *Nature* 2017; 549:543–547.
57. Piunti A, Shilatfard A. Epigenetic balance of gene expression by Polycomb and COMPASS families. *Science* 2016; 352:aad9780.
58. Riising EM, Comet I, Leblanc B, *et al.* Gene silencing triggers polycomb repressive complex 2 recruitment to CpG islands genome wide. *Mol Cell* 2014; 55:347–360.
59. Wang L, Brown JL, Cao R, *et al.* Hierarchical recruitment of polycomb group silencing complexes. *Mol Cell* 2004; 14:637–646.
60. Pengelly AR, Copur O, Jackle H, *et al.* A histone mutant reproduces the phenotype caused by loss of histone-modifying factor Polycomb. *Science* 2013; 339:698–699.
61. Tamburri S, Lavarone E, Fernandez-Perez D, *et al.* Histone H2AK119 monoubiquitination is essential for polycomb-mediated transcriptional repression. *Mol Cell* 2020; 77:840.e5–856.e5.
62. Cao R, Wang L, Wang H, *et al.* Role of histone H3 lysine 27 methylation in Polycomb-group silencing. *Science* 2002; 298:1039–1043.
63. Kuzmichev A, Nishioka K, Erdjument-Bromage H, *et al.* Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. *Genes Dev* 2002; 16:2893–2905.
64. Mei H, Kozuka C, Hayashi R, *et al.* H2AK119ub1 guides maternal inheritance ■ and zygotic deposition of H3K27me3 in mouse embryos. *Nat Genet* 2021; 53:539–550.
- This article together with reference [65■] dissects the temporal dynamics and between PRC1 and PRC2 during oocyte growth and after fertilization. Although in oocytes, depletion of PRC1 subunits causes loss of H2AK119Ub1 and leaves H3K27me3 largely unaffected, in the preimplantation embryo there is a dependence of H3K27me3 on the preceding H2AK119Ub1. These results show that PRC1 functions in regulating PRC2 activity after fertilization.
65. Chen Z, Djekidel MN, Zhang Y. Distinct dynamics and functions of ■ H2AK119ub1 and H3K27me3 in mouse preimplantation embryos. *Nat Genet* 2021; 53:551–563.
- The authors deplete the catalytic subunit of PRC2, and show that consequent loss of H3K27me3 in the early embryo leaves H2AK119Ub1 mostly unaffected. Additionally, the acute loss of H2AK119Ub1 in the zygote leaves H3K27me3 unaffected until the four-cell stage where the embryos arrest, suggesting together with reference [64■] that the PRC1-mediated patterning occurs in the oocyte before fertilization.
66. Zheng H, Huang B, Zhang B, *et al.* Resetting epigenetic memory by reprogramming of histone modifications in mammals. *Mol Cell* 2016; 63:1066–1079.
67. Santos F, Peters AH, Otte AP, *et al.* Dynamic chromatin modifications characterise the first cell cycle in mouse embryos. *Dev Biol* 2005; 280:225–236.
68. Inoue A, Jiang L, Lu F, Zhang Y. Genomic imprinting of Xist by maternal H3K27me3. *Genes Dev* 2017; 31:1927–1932.
69. Faust C, Lawson KA, Schork NJ, *et al.* The Polycomb-group gene *eed* is required for normal morphogenetic movements during gastrulation in the mouse embryo. *Development* 1998; 125:4495–4506.
70. O'Carroll D, Erhardt S, Pagani M, *et al.* The polycomb-group gene *Ezh2* is required for early mouse development. *Mol Cell Biol* 2001; 21:4330–4336.
71. Blackledge NP, Farcas AM, Kondo T, *et al.* Variant PRC1 complex-dependent H2A ubiquitylation drives PRC2 recruitment and polycomb domain formation. *Cell* 2014; 157:1445–1459.
72. Tavares L, Dimitrova E, Oxley D, *et al.* RYBP-PRC1 complexes mediate H2A ubiquitylation at polycomb target sites independently of PRC2 and H3K27me3. *Cell* 2012; 148:664–678.
73. Dahl JA, Jung I, Aanes H, *et al.* Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition. *Nature* 2016; 537:548–552.
74. Zhang B, Zheng H, Huang B, *et al.* Allelic reprogramming of the histone modification H3K4me3 in early mammalian development. *Nature* 2016; 537:553–557.
75. Andreu-Vieyra CV, Chen R, Agno JE, *et al.* MLL2 is required in oocytes for bulk histone 3 lysine 4 trimethylation and transcriptional silencing. *PLoS Biol* 2010; 8.
76. Hanna CW, Taudt A, Huang J, *et al.* MLL2 conveys transcription-independent ■ H3K4 trimethylation in oocytes. *Nat Struct Mol Biol* 2018; 25:73–82.
- The authors profile the establishment of the noncanonical pattern of H3K4me3 in oocytes and find that the patterning occurs independent of transcriptional status. The noncanonical deposition of H3K4me3 is deposited by MLL2, and this chromatin mark can spread to regions marked by DNA methylation in the absence of DNA methyltransferases.
77. Fadloun A, Le Gras S, Jost B, *et al.* Chromatin signatures and retrotransposon profiling in mouse embryos reveal regulation of LINE-1 by RNA. *Nat Struct Mol Biol* 2013; 20:332–338.
78. Liu X, Wang C, Liu W, *et al.* Distinct features of H3K4me3 and H3K27me3 chromatin domains in preimplantation embryos. *Nature* 2016; 537:558–562.
79. Alder O, Laval F, Helness A, *et al.* Ring1B and Suv39h1 delineate distinct chromatin states at bivalent genes during early mouse lineage commitment. *Development* 2010; 137:2483–2492.
80. Rugg-Gunn PJ, Cox BJ, Ralston A, Rossant J. Distinct histone modifications in stem cell lines and tissue lineages from the early mouse embryo. *Proc Natl Acad Sci U S A* 2010; 107:10783–10790.
81. Lawrence PA, Levine M. Mosaic and regulative development: two faces of one coin. *Curr Biol* 2006; 16:R236–R239.